Access to subsidised CAR T-cell therapy tisagenlecleucel (Kymriah) will be expanded to include adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma and primary mediastinal B cell lymphoma. Previously, subsidised therapy was only provided to children and young adults with acute lymphoblastic leukaemia (ALL). The announcement from the Federal ...
CAR T-cell therapy access expands to DLBCL patients as local manufacture starts
By Mardi Chapman
30 Jan 2020